Be a part of our medical cannabis research study!


Key Research Findings
Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. (2011)
  • “Chronic non-cancer pain conditions included neuropathic pain, fibromyalgia, rheumatoid arthritis, and mixed chronic pain.”
  • “Overall the quality of trials was excellent. Fifteen of the eighteen trials that met the inclusion criteria demonstrated a significant analgesic effect of cannabinoid as compared with placebo and several reported significant improvements in sleep.”
  • “There were no serious adverse effects. Adverse effects most commonly reported were generally well tolerated, mild to moderate in severity and led to withdrawal from the studies in only a few cases.”
  • “Overall there is evidence that cannabinoids are safe and modestly effective in neuropathic pain with preliminary evidence of efficacy in fibromyalgia and rheumatoid arthritis.”
Cannabis Use in Patients with Fibromyalgia: Effect on Symptoms Relief and Health-Related Quality of Life (2011)
  • “This observational study provides information on the patterns of cannabis use for therapeutic purposes among a group of patients with FM. Most of them were middle-aged women that did not respond to current treatment and self-administered marijuana, devoid of medical advice.”
  • 28 people with fibromyalgia who were herbal cannabis users and 28 non-users, without differences in demographics and clinical variables, were compared. After two hours of cannabis use, there was a statistically significant reduction of pain and stiffness, enhancement of relaxation and an increase in somnolence and feeling of well-being (all P values < 0.001). 
Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief. (2006)
  • Daily recorded pain of the people with fibromyalgia was significantly reduced over a three-month period.
Tetrahydrocannabinol (Delta 9-THC) Treatment in Chronic Central Neuropathic Pain and Fibromyalgia Patients: Results of a Multicenter Survey. (2009)
  • One case series of 172 participants reported from Germany included 32 people with fibromyalgia. On average, participants received delta 9-THC 7.5 mg over seven months.
  • “In our patient sample, THC treatment led to a significant reduction in pain intensity. Noteworthy, this effect could be observed when a mean daily dose of 7.5 mg THC was administered. This dosage shows high acceptance and efficacy.”
Clinical endocannabinoid deficiency reconsidered: current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes. (2016)

Sign up to receive emails about promotions, events, policy reform, and more!

You have successfully subscribed to Om's mailing list!

There was an error while trying to send your request. Please try again.

Om of Medicine will use the information you provide on this form to be in touch with you and to provide updates and marketing.